Cargando…
A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
BACKGROUND: Successful chemoprevention or chemotherapy is achieved through targeted delivery of prophylactic agents during initial phases of carcinogenesis or therapeutic agents to malignant tumors. Bacteria can be used as anticancer agents, but efforts to utilize attenuated pathogenic bacteria suff...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157686/ https://www.ncbi.nlm.nih.gov/pubmed/34039418 http://dx.doi.org/10.1186/s40168-021-01071-4 |
_version_ | 1783699737432555520 |
---|---|
author | Chung, Yusook Ryu, Yongku An, Byung Chull Yoon, Yeo-Sang Choi, Oksik Kim, Tai Yeub Yoon, Jaekyung Ahn, Jun Young Park, Ho Jin Kwon, Soon-Kyeong Kim, Jihyun F. Chung, Myung Jun |
author_facet | Chung, Yusook Ryu, Yongku An, Byung Chull Yoon, Yeo-Sang Choi, Oksik Kim, Tai Yeub Yoon, Jaekyung Ahn, Jun Young Park, Ho Jin Kwon, Soon-Kyeong Kim, Jihyun F. Chung, Myung Jun |
author_sort | Chung, Yusook |
collection | PubMed |
description | BACKGROUND: Successful chemoprevention or chemotherapy is achieved through targeted delivery of prophylactic agents during initial phases of carcinogenesis or therapeutic agents to malignant tumors. Bacteria can be used as anticancer agents, but efforts to utilize attenuated pathogenic bacteria suffer from the risk of toxicity or infection. Lactic acid bacteria are safe to eat and often confer health benefits, making them ideal candidates for live vehicles engineered to deliver anticancer drugs. RESULTS: In this study, we developed an effective bacterial drug delivery system for colorectal cancer (CRC) therapy using the lactic acid bacterium Pediococcus pentosaceus. It is equipped with dual gene cassettes driven by a strong inducible promoter that encode the therapeutic protein P8 fused to a secretion signal peptide and a complementation system. In an inducible CRC cell-derived xenograft mouse model, our synthetic probiotic significantly reduced tumor volume and inhibited tumor growth relative to the control. Mice with colitis-associated CRC induced by azoxymethane and dextran sodium sulfate exhibited polyp regression and recovered taxonomic diversity when the engineered bacterium was orally administered. Further, the synthetic probiotic modulated gut microbiota and alleviated the chemically induced dysbiosis. Correlation analysis demonstrated that specific bacterial taxa potentially associated with eubiosis or dysbiosis, such as Akkermansia or Turicibacter, have positive or negative relationships with other microbial members. CONCLUSIONS: Taken together, our work illustrates that an effective and stable synthetic probiotic composed of P. pentosaceus and the P8 therapeutic protein can reduce CRC and contribute to rebiosis, and the validity and feasibility of cell-based designer biopharmaceuticals for both treating CRC and ameliorating impaired microbiota. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01071-4. |
format | Online Article Text |
id | pubmed-8157686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81576862021-05-28 A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota Chung, Yusook Ryu, Yongku An, Byung Chull Yoon, Yeo-Sang Choi, Oksik Kim, Tai Yeub Yoon, Jaekyung Ahn, Jun Young Park, Ho Jin Kwon, Soon-Kyeong Kim, Jihyun F. Chung, Myung Jun Microbiome Research BACKGROUND: Successful chemoprevention or chemotherapy is achieved through targeted delivery of prophylactic agents during initial phases of carcinogenesis or therapeutic agents to malignant tumors. Bacteria can be used as anticancer agents, but efforts to utilize attenuated pathogenic bacteria suffer from the risk of toxicity or infection. Lactic acid bacteria are safe to eat and often confer health benefits, making them ideal candidates for live vehicles engineered to deliver anticancer drugs. RESULTS: In this study, we developed an effective bacterial drug delivery system for colorectal cancer (CRC) therapy using the lactic acid bacterium Pediococcus pentosaceus. It is equipped with dual gene cassettes driven by a strong inducible promoter that encode the therapeutic protein P8 fused to a secretion signal peptide and a complementation system. In an inducible CRC cell-derived xenograft mouse model, our synthetic probiotic significantly reduced tumor volume and inhibited tumor growth relative to the control. Mice with colitis-associated CRC induced by azoxymethane and dextran sodium sulfate exhibited polyp regression and recovered taxonomic diversity when the engineered bacterium was orally administered. Further, the synthetic probiotic modulated gut microbiota and alleviated the chemically induced dysbiosis. Correlation analysis demonstrated that specific bacterial taxa potentially associated with eubiosis or dysbiosis, such as Akkermansia or Turicibacter, have positive or negative relationships with other microbial members. CONCLUSIONS: Taken together, our work illustrates that an effective and stable synthetic probiotic composed of P. pentosaceus and the P8 therapeutic protein can reduce CRC and contribute to rebiosis, and the validity and feasibility of cell-based designer biopharmaceuticals for both treating CRC and ameliorating impaired microbiota. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01071-4. BioMed Central 2021-05-26 /pmc/articles/PMC8157686/ /pubmed/34039418 http://dx.doi.org/10.1186/s40168-021-01071-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chung, Yusook Ryu, Yongku An, Byung Chull Yoon, Yeo-Sang Choi, Oksik Kim, Tai Yeub Yoon, Jaekyung Ahn, Jun Young Park, Ho Jin Kwon, Soon-Kyeong Kim, Jihyun F. Chung, Myung Jun A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota |
title | A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota |
title_full | A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota |
title_fullStr | A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota |
title_full_unstemmed | A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota |
title_short | A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota |
title_sort | synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157686/ https://www.ncbi.nlm.nih.gov/pubmed/34039418 http://dx.doi.org/10.1186/s40168-021-01071-4 |
work_keys_str_mv | AT chungyusook asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT ryuyongku asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT anbyungchull asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT yoonyeosang asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT choioksik asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT kimtaiyeub asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT yoonjaekyung asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT ahnjunyoung asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT parkhojin asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT kwonsoonkyeong asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT kimjihyunf asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT chungmyungjun asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT chungyusook syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT ryuyongku syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT anbyungchull syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT yoonyeosang syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT choioksik syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT kimtaiyeub syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT yoonjaekyung syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT ahnjunyoung syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT parkhojin syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT kwonsoonkyeong syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT kimjihyunf syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota AT chungmyungjun syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota |